Ginkgo Bioworks—a synthetic biology company—is the leading horizontal platform for cell programming. Customers across industries leverage Ginkgo’s platform to grow the future. We work across industries helping companies to design, develop, and optimize products for a breadth of commercial applications. We help our partners develop biological treatments and processes that detect and sequester pollutants, upcycle organic waste streams, move toward net zero water, and so much more.
In 2021, Ginkgo began trading publicly on the NYSE ($DNA) after raising $1.6 billion. Our physical footprint now includes offices and labs across the United States, Europe, and Australia. We believe the microbes, chemicals, and sensors developed through synthetic biology can drive down your cost of goods and services, strengthen supply chains to increase your company’s resiliency, and take advantage of new market opportunities. Our mission is to make biology easier to engineer so that your company can more easily access the immense and largely unexplored value of biology.
Web URL: https://www.ginkgobioworks.com/
